Loading... Please wait...
Sort by:
  • Multiple Sclerosis: Update Bulletin [June 2014]
    Learn More Multiple Sclerosis: Update Bulletin [June 2014]
    Gain new KOL insights on the latest events happening in Multiple Sclerosis: CHMP recommends EU label expansion of Novartis' Gilenya Highlights from this event update bulletin CHMP recommends EU label expansion...
  • COPD: Update Bulletin [June 2014]
    Learn More COPD: Update Bulletin [June 2014]
    Gain new KOL insights on the latest events happening in  COPD: GlaxoSmithKline’s Anoro approved in Europe for the treatment of COPD Highlights from this event update bulletin GlaxoSmithKline’s...
  • Prostate Cancer: Update Bulletin [June 2014]
    Learn More Prostate Cancer: Update Bulletin [June 2014]
    Gain new KOL insights on the latest events happening in Prostate Cancer: PREVAIL trial data position Xtandi for approval in pre-chemo setting Highlights from this event update bulletin PREVAIL trial data...
  • HIV: KOL Insight  and Consensus Outlook
    Learn More HIV: KOL Insight and Consensus Outlook
    HIV: KOL Insight and Consensus Outlook examines what frontline clinicians really think about current HIV treatment pathways, addresses the most pressing unmet needs the industry can respond to and gives insight into...
  • Diabetes -- KOL Insight  and Consensus Outlook
    Learn More Diabetes -- KOL Insight and Consensus Outlook
    FirstWord’s Therapy Trends: Diabetes offers a complete ongoing analysis of current trends, future forecasts and landscape modifiers. Gain instant access to an accurate, unbiased, qualitative review of the latest...
  • Hepatitis C: KOL Insight and Consensus Outlook
    Learn More Hepatitis C: KOL Insight and Consensus Outlook
    Approval of Gilead’s once daily oral nucleotide inhibitor Sovaldi marks a significant step in the treatment of hepatitis C (HCV). With efficacy over 90% in GT1/2/3/4 patients, this safe, best in class therapy...
  • Hepatitis C: Consensus Outlook
    Learn More Hepatitis C: Consensus Outlook
    The worldwide hepatitis C (HCV) market is forecasted to grow to $17.7 billion in 2017.  The catalysts for this growth include a boost in diagnosis rates following an increase in screening, and the introduction more...
  • Colorectal Cancer: KOL Insight
    Learn More Colorectal Cancer: KOL Insight
    The global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in cytotoxics and increasing adoption of anti-EGFR products as first line therapies. What will be...
  • Diabetes: Consensus Outlook
    Learn More Diabetes: Consensus Outlook
    Therapy Trends Consensus Outlook: Diabetes is an in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and...
  • Diabetes: KOL Insight
    Learn More Diabetes: KOL Insight
    Therapy Trends KOL Insight: Diabetes analyses the current and predicted key issues, current products and late-stage pipeline product and gives you qualitative information based on exclusive interviews with 12 key...
  • Alzheimer’s disease: KOL Insight
    Learn More Alzheimer’s disease: KOL Insight
    In 2012, the Alzheimer’s disease (AD) market was dealt a huge blow following negative results from pivotal Phase III trials of Pfizer and J&J’s bapineuzumab and the intravenous formulation of the drug was...

customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved